Publications by authors named "Victor A Levin"

Claim this Profile
S
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Howard Colman, Giuseppe Lombardi, Eric T Wong, Tobias Walbert, Marica Eoli, Victor A Levin

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in neuro-oncology: contributions of the Asilomar Conference on brain tumor research and therapy.
Manfred Westphal, Victor A Levin, Mitchel S Berger, Russell Pieper, Ryo Nishikawa

J Neurosurg· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory.
Benjamin M Ellingson, Victor A Levin, Timothy F Cloughesy

Neurotherapeutics· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells.
Noymi Yam, Jason Levin, Zhengzheng Bao, Wubin Qian, Victor A Levin

Oncotarget· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Huanwen Chen, John Kuhn, Kathleen R Lamborn, Lauren E Abrey, Lisa M DeAngelis, Victor A Levin

Neurooncol Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How far will the Voyager take us?
Victor A Levin

CNS Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.
Victor A Levin, Sandra E Ictech, Kenneth R Hess

CNS Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding brain penetrance of anticancer drugs.
Victor A Levin, Benjamin M Ellingson

Neuro Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug discovery in neuro-oncology: challenges in the path forward.
Victor A Levin

Neuro Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, Mark Gilbert, Lauren E Abrey, Victor A Levin

J Neurooncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain

J Neurooncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Anticancer Drug Discovery and Development: 2016 conference insights.
Victor A Levin, Lauren E Abrey, Timothy P Heffron, Peter J Tonge, Arvin C Dar

CNS Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized medicine in neuro-oncology.
Victor A Levin

CNS Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Anticancer Drug Discovery and Development Conference White Paper.
Victor A Levin, Peter J Tonge, James M Gallo, Marc R Birtwistle, Arvin C Dar

Neuro Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Victor A Levin

Oncology (Williston Park)· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
Victor A Levin, Nancy D Mendelssohn, James Chan, Mady C Stovall, Scott J Peak

J Neurooncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Marta Penas-Prado, Kenneth R Hess, Michael J Fisch, Lore W Lagrone, Morris D Groves, Victor A Levin

Neuro Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting more out of survival data by using the hazard function.
Kenneth R Hess, Victor A Levin

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new?
Victor A Levin

Oncology (Williston Park)· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, Lauren Abrey, Lisa M DeAngelis, Victor A Levin

Neuro Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ask the Experts: How best to treat recurrent glioma.
Victor Alan Levin

CNS Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
Pierre Giglio, Megha Dhamne, Kenneth R Hess, Mark R Gilbert, Morris D Groves, Victor A Levin

Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic approach to the management of patients with brain metastases of known or unknown primary site.
Athanassios P Kyritsis, Sofia Markoula, Victor A Levin

Cancer Chemother Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
Victor A Levin, Sonali Panchabhai, Li Shen, Keith A Baggerly

Proteome Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Athanassios P Kyritsis, Victor A Levin

Cancer Chemother Pharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis